Amcp Nexus National Harbor

Calendar | AMCP.org

This Month's Issue Vol. Volume 29, Number 7. Upcoming Member Events AMCP Market Insights - Impact of Mental health in Patients with Rare Disease. A Targeted Treatment for mIDH Glioma. Moderna's RSV vaccine candidate under investigation. Utilizing the Pre-Approval Safe Harbor Information to Accelerate Access for Patients. A new first-line treatment for unresectable or metastatic hepatocellular carcinoma.

The United States: Trends in Asthma Hospitalizations, Medical Costs and Mortality after the Introduction of Biotic Drugs.

-.

The webinar will present key insights from a recent Market Insights Roundtable Discussion hosted by AMCP. Experts and thought leaders met to discuss the often overlooked connection between mental illness and rare diseases. The panelists discussed the mental health challenges that individuals with rare diseases face, as well as the effects of these conditions on their mental wellbeing. They also explored strategies for improving holistic patient care.

A Pre-Approval Information Exchange Webinar (PIE), sponsored by Servier.

Servier, a leading global pharmaceutical company, is pleased to present vorasidenib as an investigational treatment option for patients with mIDH glioma. Vorasidenib, a potential first-in class targeted therapy for mIDH glioma was granted a fast track designation by FDA. A PDUFA is expected in Q3 of 2024. This webinar will give an overview of mIDH glioma, and highlight the clinical data of vorasidenib.